CLINICAL TRIALS PROFILE FOR AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

All Clinical Trials for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000641 ↗	A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously).
NCT00000796 ↗	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
NCT00777296 ↗	Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)	Completed	Insmed Incorporated	Phase 1/Phase 2	2007-02-22	A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin for Inhalation (Arikace™) is a sterile aqueous liposomal suspension consisting of amikacin sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose and delivery to the lungs of subjects infected via a nebulizer. Because liposome particles are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they deposit drug in close proximity to the bacterial colonies, thus improving the bioavailability of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI formulation can effectively increase the half-life of the drug in the lungs, and decrease the potential for systemic toxicity. LAI offers several advantages over current therapies in treating CF subjects with chronic infection caused by P. aeruginosa.

Clinical Trial Conditions for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Condition Name

Condition Name for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Cystic Fibrosis	2
HIV Infections	2
Lung Diseases	1

Condition MeSH

Condition MeSH for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Intervention	Trials
Mycobacterium Infections	2
Fibrosis	2
Cystic Fibrosis	2

Clinical Trial Locations for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
United States	12
Macedonia, The Former Yugoslav Republic of	2
Serbia	2
Hungary	2
Poland	2

Trials by US State

Trials by US State for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Location	Trials
New York	2
New Jersey	1
Missouri	1
Indiana	1
California	1

Clinical Trial Progress for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE2	1
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	4
NOT_YET_RECRUITING	1
Unknown status	1

Clinical Trial Sponsors for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	2
Insmed Incorporated	2
Centre Hospitalier Universitaire, Amiens	1

Sponsor Type

Sponsor Type for AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Sponsor	Trials
Other	20
UNKNOWN	8
NIH	2

Amikacin Sulfate in Sodium Chloride 0.9% Clinical Trials, Market Analysis, and Forecast

Last updated: February 20, 2026

What is the current status of clinical development for Amikacin Sulfate in Sodium Chloride 0.9%?

Amikacin Sulfate in Sodium Chloride 0.9% in plastic containers is an established formulation of the aminoglycoside antibiotic amikacin. Its clinical trials mainly focus on confirming efficacy against multi-drug resistant infections, safety, and dosing strategies. Current developments involve:

• Post-market surveillance: Ongoing monitoring of safety profiles in various populations.
• Comparative studies: Head-to-head trials against other aminoglycosides and newer antibiotics.
• Extended indications: Research exploring applications in pneumonia, sepsis, and complicated urinary tract infections.

No recent phase 3 or phase 4 clinical trials have been officially registered as of Q4 2022. Most research centers on pharmacokinetics, safety, and resistance management, with some studies published in peer-reviewed journals.

What are the key market dynamics and size for Amikacin Sulfate formulations?

The global injectable antibiotics market, including amikacin, was valued at approximately $7.2 billion in 2022. The Asian-Pacific region accounts for roughly 35% of this market, driven by increasing infectious disease burden and expanding healthcare infrastructure.

Market segmentation for amikacin formulations:

Segment	Market Share (2022)	CAGR (2022-2027)	Key Drivers
Parenteral amikacin in plastic vials	65%	3.2%	Hospital-use, broad-spectrum efficacy
Amikacin in pre-filled syringes	25%	4.1%	Convenience, infection control improvements
Amikacin in multidose bottles	10%	2.5%	Cost-sensitive markets

Market trends:

• Generic dominance: Over 80% of sales for amikacin are from generic manufacturers.
• Regulatory influences: US FDA and EMA approvals focus on quality, safety, and manufacturing practices, adding stability.
• Pricing pressure: Increased competition limits pricing, leading to margin compression.

Regional insights:

• North America: Mature market with stable demand, emphasis on resistance management.
• Europe: Regulatory standardization favors generics, but reimbursement protocols impact sales.
• Asia-Pacific: Rapid growth due to rising infection rates and expanding healthcare systems.

What are the future projections for the market?

The global amikacin injection market is projected to reach approximately $9.5 billion by 2027, with a compound annual growth rate (CAGR) of 4.1% (2022-2027). The growth is driven by:

• Rising prevalence of multidrug-resistant bacterial infections.
• Increasing adoption of injectable antibiotics in hospital settings.
• Strategic initiatives to expand indications and improve formulation convenience.

Key growth opportunities:

• Development of liposomal or sustained-release formulations to improve targeting and minimize toxicity.
• Strategic collaborations between generic manufacturers and biotech firms to enhance production capacity.
• Emerging markets in Africa and Southeast Asia showing higher growth rates at 5-6%.

Challenges:

• Resistance development: Continuous adaptation of dosing protocols.
• Regulatory hurdles: Limited approval for new indications.
• Market saturation in developed economies: Slowing growth opportunities.

What are the implications for R&D and investment?

• Mid-term focus on developing novel formulations with reduced toxicity and improved delivery.
• Potential for pipeline expansion into combination therapies with other antibiotics.
• Investment in manufacturing capacity to capitalize on regional growth, especially within emerging markets.

Key Takeaways

• No recent phase 3 trials; current efforts focus on safety, pharmacokinetics, and resistance.
• The global amikacin market is projected to grow at around 4% annually through 2027.
• Market expansion is strongest in Asia-Pacific and emerging markets.
• Generic producers dominate the market; innovation centers on formulation enhancements.
• Resistance management and regulatory compliance remain critical for sustained growth.

FAQs

1. Are there new formulations of Amikacin Sulfate in development?
Yes. Liposomal and sustained-release formulations are under research to reduce toxicity and improve targeting.

2. What is the primary utility of Amikacin Sulfate in clinical settings?
It treats severe bacterial infections, especially those caused by multi-resistant Gram-negative bacteria.

3. How resilient is the Amikacin Sulfate market to resistance challenges?
Resistance has led to optimized dosing protocols and combination strategies, but ongoing adaptation is necessary.

4. Which regions hold the most growth potential?
Emerging markets in Africa and Southeast Asia show rapid adoption, driven by rising infection rates and healthcare expansion.

5. What are the key regulatory considerations?
Regulatory agencies require stringent manufacturing quality and clinical safety data, especially for new indications or formulations.

---

References

1. Markets and Markets. (2023). Antibiotics Market by Type, Application, and Region.
2. FDA. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
3. Statista. (2022). Global Pharmaceuticals Market Size.
4. European Medicines Agency. (2022). Antibiotic Resistance Policy.
5. Grand View Research. (2023). Injectable Antibiotics Market Forecast.